Theseus Pharmaceuticals Inc

NASDAQ THRX

Download Data

Theseus Pharmaceuticals Inc Return on Tangible Equity (ROTE) 3 year CAGR for the year ending September 19, 2024

Theseus Pharmaceuticals Inc Return on Tangible Equity (ROTE) 3 year CAGR is NA for the year ending September 19, 2024. Return on tangible equity measures the profitability of a company relative to its tangible equity, which is shareholders' equity minus goodwill and intangible assets. It is calculated by dividing the net income by the tangible equity. This ratio indicates the return generated for each unit of tangible equity invested by the shareholders. A higher return on tangible equity suggests better profitability and value creation for the shareholders' tangible investment. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date Oct. 7, 2021
Location United States
Headquarters 245 Main Street, Cambridge, MA, United States, 02142
Employees 38
Sector Healthcare
Industry Biotechnology
Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Similar companies

IPSC

Century Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email